Literature DB >> 24526315

Significance of platelet and AFP levels and liver function parameters for HCC size and survival.

Brian I Carr1, Vito Guerra, Edoardo G Giannini, Fabio Farinati, Francesca Ciccarese, Gian Ludovico Rapaccini, Maria Di Marco, Luisa Benvegnù, Marco Zoli, Franco Borzio, Eugenio Caturelli, Maria Chiaramonte, Franco Trevisani.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) is a heterogeneous disease with both tumor and liver factors being involved. AIMS: To investigate HCC clinical phenotypes and factors related to HCC size.
METHODS: Prospectively-collected HCC patients' data from a large Italian database were arranged according to the maximum tumor diameter (MTD) and divided into tumor size terciles, which were then compared in terms of several common clinical parameters and patients' survival.
RESULTS: An higer MTD tercile was significantly associated with increased blood alpha-fetoprotein (AFP), gamma-glutamyl transpeptidase (GGTP), and platelet levels. Patients with higher platelet levels had larger tumors and higher GGTP levels, with lower bilirubin levels. However, patients with the highest AFP levels had larger tumors and higher bilirubin levels, reflecting an aggressive biology. AFP correlation analysis revealed the existence of 2 different groups of patients: those with higher and with lower AFP levels, each with different patient and tumor characteristics. The Cox proportional-hazard model showed that a higher risk of death was correlated with GGTP and bilirubin levels, tumor size and number, and portal vein thrombosis (PVT), but not with AFP or platelet levels.
CONCLUSIONS: An increased tumor size was associated with increased blood platelet counts, AFP and GGTP levels. Platelet and AFP levels were important indicators of tumor size, but not of survival.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24526315     DOI: 10.5301/jbm.5000064

Source DB:  PubMed          Journal:  Int J Biol Markers        ISSN: 0393-6155            Impact factor:   2.659


  15 in total

1.  HCC with low- and normal-serum alpha-fetoprotein levels.

Authors:  Brian I Carr; Hikmet Akkiz; Oguz Üsküdar; Kendal Yalçın; Vito Guerra; Sedef Kuran; Ümit Karaoğullarından; Engin Altıntaş; Ayşegül Özakyol; Salih Tokmak; Tuğsan Ballı; Mehmet Yücesoy; Halil İbrahim Bahçeci; Abdulalh Ülkü; Tolga Akçam; Kamil Yalçın Polat; Nazım Ekinci; Halis Şimşek; Necati Örmeci; Abdulalh Sonsuz; Mehmet Demir; Murat Kılıç; Ahmet Uygun; Ali Demir; Anıl Delik; Burcu Arslan; Figen Doran; Sezai Yilmaz; Yaman Tokat
Journal:  Clin Pract (Lond)       Date:  2018

2.  Relationships Between Indices of Tumor Aggressiveness in Hepatocellular Carcinoma.

Authors:  Brian I Carr; Vito Guerra; Rossella Donghia; Seai Yilmaz
Journal:  J Gastrointest Cancer       Date:  2021-10-06

3.  Low Alpha-Fetoprotein Levels Are Associated with Improved Survival in Hepatocellular Carcinoma Patients with Portal Vein Thrombosis.

Authors:  Brian I Carr; Vito Guerra
Journal:  Dig Dis Sci       Date:  2015-11-17       Impact factor: 3.199

4.  High expression of IL-1β and NFκB in tumor tissue predicts a low recurrence rate of hepatocellular carcinoma.

Authors:  Bangxu Yu; Aiqin Li; Mao Zhang; Haoran Li; Cheng Tao; Bing Han
Journal:  Int J Clin Exp Pathol       Date:  2018-12-01

5.  Soluble MICB protein levels and platelet counts during hepatitis B virus infection and response to hepatocellular carcinoma treatment.

Authors:  Hoang Van Tong; Le Huu Song; Nghiem Xuan Hoan; Bui Khac Cuong; Bui Tien Sy; Ho Anh Son; Do Quyet; Vu Quoc Binh; Peter G Kremsner; Claus Thomas Bock; Thirumalaisamy P Velavan; Nguyen Linh Toan
Journal:  BMC Infect Dis       Date:  2015-01-23       Impact factor: 3.090

6.  Decreased expression of long non-coding RNA LOC728290 in human hepatocellular carcinoma.

Authors:  Shao-Geng Zhang; Yu-Feng Li; Na-Na Zhao; Cheng-Cai Lai; Si-Jie Cheng; Jin Yan; Peirui Zhang; Zhaohai Wang; Xi-Liang Wang; Peng-Hui Yang
Journal:  Oncol Lett       Date:  2017-08-18       Impact factor: 2.967

7.  A Liver Index and its Relationship to Indices of HCC Aggressiveness.

Authors:  Brian I Carr; Vito Guerra; Edoardo G Giannini; Fabio Farinati; Francesca Ciccarese; Gian Ludovico Rapaccini; Maria Di Marco; Luisa Benvegnù; Marco Zoli; Franco Borzio; Eugenio Caturelli; Alberto Masotto; Franco Trevisani
Journal:  J Integr Oncol       Date:  2016-09-05

8.  A Nomogram-Based Prognostic Model for Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib: A Multicenter Study.

Authors:  Giovanni Marasco; Francesco Poggioli; Antonio Colecchia; Giuseppe Cabibbo; Filippo Pelizzaro; Edoardo Giovanni Giannini; Sara Marinelli; Gian Ludovico Rapaccini; Eugenio Caturelli; Mariella Di Marco; Elisabetta Biasini; Fabio Marra; Filomena Morisco; Francesco Giuseppe Foschi; Marco Zoli; Antonio Gasbarrini; Gianluca Svegliati Baroni; Alberto Masotto; Rodolfo Sacco; Giovanni Raimondo; Francesco Azzaroli; Andrea Mega; Gianpaolo Vidili; Maurizia Rossana Brunetto; Gerardo Nardone; Luigina Vanessa Alemanni; Elton Dajti; Federico Ravaioli; Davide Festi; Franco Trevisani; On Behalf Of The Italian Liver Cancer Ita Li Ca Group
Journal:  Cancers (Basel)       Date:  2021-05-29       Impact factor: 6.639

9.  Resistance to multikinase inhibitor actions mediated by insulin like growth factor-1.

Authors:  Catia Lippolis; Maria Grazia Refolo; Rosalba D'Alessandro; Nicola Carella; Caterina Messa; Aldo Cavallini; Brian Irving Carr
Journal:  J Exp Clin Cancer Res       Date:  2015-09-02

10.  Derived neutrophil to lymphocyte ratio predicts prognosis for patients with HBV-associated hepatocellular carcinoma following transarterial chemoembolization.

Authors:  Dongsheng Zhou; Jianzhong Liang; L I Xu; Fengying He; Zhongguo Zhou; Yaojun Zhang; Minshan Chen
Journal:  Oncol Lett       Date:  2016-03-21       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.